These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20594535)

  • 1. [Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes].
    Nørgaard K; Sohlberg A; Goodall G
    Ugeskr Laeger; 2010 Jul; 172(27):2020-5. PubMed ID: 20594535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada.
    St Charles ME; Sadri H; Minshall ME; Tunis SL
    Clin Ther; 2009 Mar; 31(3):657-67. PubMed ID: 19393856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review.
    Roze S; Smith-Palmer J; Valentine W; de Portu S; Nørgaard K; Pickup JC
    Diabet Med; 2015 Nov; 32(11):1415-24. PubMed ID: 25962621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
    Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
    Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
    Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
    Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
    Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
    Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Outcome and Cost-Effectiveness Analysis of CSII Versus MDI in Children and Adolescent With Type 1 Diabetes Mellitus in a Public Health Care System of China.
    Hu S; Yang H; Chen Z; Leng X; Li C; Qiao L; Lv W; Li T
    Front Endocrinol (Lausanne); 2021; 12():604028. PubMed ID: 33859614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
    Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
    Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
    J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with type 1 diabetes.
    Zhang L; Leng X; Tian F; Xiao D; Xuan J; Yang H; Liu J; Chen Z
    Postgrad Med; 2022 Aug; 134(6):627-634. PubMed ID: 35695267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
    Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
    Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
    St Charles M; Lynch P; Graham C; Minshall ME
    Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
    Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
    Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.
    Colquitt JL; Green C; Sidhu MK; Hartwell D; Waugh N
    Health Technol Assess; 2004 Oct; 8(43):iii, 1-171. PubMed ID: 15488165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.
    Giménez M; Elías I; Álvarez M; Quirós C; Conget I
    Endocrinol Diabetes Nutr; 2017; 64(7):377-383. PubMed ID: 28745609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Event and Cost Offsets of Switching 20% of the Type 1 Diabetes Population in Germany From Multiple Daily Injections to Continuous Subcutaneous Insulin Infusion: A 4-Year Simulation Model.
    Zöllner YF; Ziegler R; Stüve M; Krumreich J; Schauf M
    J Diabetes Sci Technol; 2016 Sep; 10(5):1142-8. PubMed ID: 26902790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.